Analyst Consensus ?
ConsensusHold28 ratings
Bullish1035.7%
Neutral1139.3%
Bearish725.0%
Globe Life Inc. · GL · FY2026 Q2 · Calendar Q3 2026
Globe Life Q2: Net Income Up 20%, EPS Guidance Raised on AI and Reinsurance Initiatives
Globe Life reported another quarter of double-digit operating income growth, with Q2 net income rising 20% to $288 million. Life premium revenue grew 7% and health premium revenue grew 16% year-over-year. The company raised FY2026 EPS guidance to $15.55-$15.95 and expanded its share repurchase program to $670-$700 million after a term-loan amendment. Management is advancing AI initiatives across underwriting, claims, and administration targeting an administrative expense ratio near 7% of premium, and progressing toward a Bermuda reinsurance subsidiary with a Q3 cession planned. EPS of $3.61 slightly missed the $3.67 consensus while revenue of $1.60 billion edged past the $1.59 billion estimate. Shares fell 7.0% the session after the report on roughly three times normal volume before recovering approximately 7% over the following sessions.
Reported After market closeNYSEFinancial Services
$14.21B market cap
100quality score
Company context
Snapshot as of publicationGlobe Life Inc. delivers diverse life insurance and supplementary health coverage, alongside annuity products, targeting households in the lower-middle to middle-income brackets throughout the United States. The company's operations are structured into four key segments: Life Insurance, Supplemental Health Insurance, Annuities, and Investments. Its offerings encompass whole life, term life, and other life protection plans; supplemental health benefits like Medicare supplements, critical illness, and accident policies; and both single-premium and flexible-premium deferred annuities. Founded in 1979 and headquartered in McKinney, Texas, the enterprise rebranded from Torchmark Corporation to Globe Life Inc. in August 2019.
Earnings scorecard
Reported versus consensus
Reported EPS
$3.61
Consensus $4
EPS surprise
-1.6%
Reported versus consensus
Reported revenue
$1.60B
Consensus $1.59B
Revenue surprise
+0.6%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$181.69Current
$90Low
$154.77Average
$200High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Jul 24, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 22, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 21, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 15, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Jul 10, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 9, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 6, 2026 |
| Truist Securities | Buy | Buy | Maintain | Apr 24, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Jul 30, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Oct 15, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Dec 19, 2022 |
| Wolfe Research | Underperform | Underperform | Maintain | Jan 21, 2022 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Apr 24, 2020 |
| B of A Securities | Buy | Buy | Maintain | Jan 23, 2020 |
| UBS | Sell | Sell | Maintain | Oct 10, 2019 |
| Goldman Sachs | Sell | Neutral | Downgrade | Sep 10, 2018 |
| Barclays | Underweight | Underweight | Maintain | Aug 11, 2017 |
| Bank of America | Underperform | Neutral | Downgrade | Nov 18, 2016 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 29, 2016 |
| Citigroup | Neutral | Neutral | Maintain | Jul 7, 2016 |
| FBR Capital | Perform | Market Perform | Maintain | Feb 8, 2016 |
| PiperJaffray | Neutral | Neutral | Maintain | Jun 2, 2015 |
| Keefe Bruyette & Woods | Perform | Market Perform | Maintain | Apr 22, 2015 |
| Sterne Agee | Neutral | Neutral | Maintain | Oct 13, 2014 |
| Scotiabank | Underperform | Sector Perform | Downgrade | Nov 22, 2013 |
| RBC Capital | Underperform | Underperform | Maintain | Jun 28, 2013 |
| Janney Capital | Neutral | Buy | Downgrade | Jun 3, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $181.69. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | Paul Newsome | $200 | $178.99 | +10.1% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $166 | $178.86 | -8.6% | Jul 10, 2026 |
| Piper Sandler | Analyst unavailable | $175 | $156.28 | -3.7% | May 26, 2026 |
| Morgan Stanley | Analyst unavailable | $181 | $155.3 | -0.4% | May 21, 2026 |
| Truist Financial | Mark Hughes | $185 | $153.55 | +1.8% | Apr 24, 2026 |
| Evercore ISI | Analyst unavailable | $157 | $144.86 | -13.6% | Feb 18, 2026 |
| Morgan Stanley | Bob Huang | $176 | $140.82 | -3.1% | Dec 15, 2025 |
| Piper Sandler | John Barnidge | $167 | $133.61 | -8.1% | Nov 21, 2025 |
| Truist Financial | Mark Hughes | $158 | $134.49 | -13.0% | Oct 24, 2025 |
| Morgan Stanley | Bob Huang | $179 | $134.91 | -1.5% | Oct 7, 2025 |
| Morgan Stanley | Analyst unavailable | $166 | $139.51 | -8.6% | Aug 5, 2025 |
| Morgan Stanley | Bob Huang | $127 | $119.38 | -30.1% | Jul 14, 2025 |
| Morgan Stanley | Analyst unavailable | $126 | $127.43 | -30.7% | Feb 28, 2025 |
| Raymond James | Wilma Burdis | $188 | $109.77 | +3.5% | Oct 15, 2024 |
| Evercore ISI | Thomas Gallagher | $95 | $104.4 | -47.7% | Sep 27, 2024 |
| Truist Financial | Mark Hughes | $90 | $90.25 | -50.5% | Jul 26, 2024 |
| CFRA | Catherine Seifert | $92 | $90.3 | -49.4% | Jul 26, 2024 |
| Piper Sandler | John Barnidge | $106 | $90.48 | -41.7% | Jul 26, 2024 |
| Morgan Stanley | Bob Huang | $65 | $81.91 | -64.2% | Jul 10, 2024 |
| Jefferies | Suneet Kamath | $90 | $81.91 | -50.5% | Jul 10, 2024 |
| Piper Sandler | John Barnidge | $110 | $82 | -39.5% | Apr 24, 2024 |
| CFRA | Catherine Seifert | $55 | $59.09 | -69.7% | Apr 12, 2024 |
| Evercore ISI | Thomas Gallagher | $75 | $49.17 | -58.7% | Apr 12, 2024 |
| Piper Sandler | John Barnidge | $86.71 | $32.8 | -52.3% | Apr 11, 2024 |
| CFRA | Catherine Seifert | $78.71 | $69.99 | -56.7% | Apr 11, 2024 |
| Evercore ISI | Thomas Gallagher | $125 | $115.99 | -31.2% | Mar 14, 2024 |
| Morgan Stanley | Analyst unavailable | $132 | $121.21 | -27.3% | Jan 10, 2023 |
| Credit Suisse | Analyst unavailable | $140 | $116.5 | -22.9% | Dec 19, 2022 |
| Morgan Stanley | Analyst unavailable | $115 | $111.6 | -36.7% | Nov 17, 2022 |
| Morgan Stanley | Analyst unavailable | $110 | $103.02 | -39.5% | Aug 17, 2022 |
| Morgan Stanley | Analyst unavailable | $109 | $97.31 | -40.0% | Jul 28, 2022 |
Track every rating change on GL the moment it posts. Free to start.
Start freeMarket reaction
event-close to next-session close
Stock move
-7.0%
Event window
SPY move
-1.2%
Same window
Abnormal move
-5.8%
Stock minus SPY
Volume
3.0×
Versus trailing sessions
Subsequent drift
+7.0%
Up to 20 sessions
GLSPY benchmark
Follow GL with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Life premium growth guidance raised from 3-3.5% to 6.5-7% for FY2026. Health premium growth guidance narrowed from 14-17% to 14-16%. FY2026 EPS guidance raised to $15.55-$15.95 per share. Share repurchase range increased from $560-$610M to $670-$700M after term-loan amendment raising principal to $450M. Q3 life underwriting margin guidance refined to exceed 50% from prior range of 49-54%. Nebraska reciprocal jurisdiction approved for Globe Life Re; Indiana approval pending. Evri (Every Health) acquisition contributing to higher health obligation ratio this quarter.
Guidance delta
Life premium growth: raised from 3-3.5% to 6.5-7%. Health premium growth: narrowed from 14-17% to 14-16%. FY2026 EPS: raised to $15.55-$15.95 per share. Share repurchases: increased from $560-$610M to $670-$700M. Q3 life underwriting margin: refined to exceed 50% from prior 49-54% range.
Key takeaways
- Q2 net income rose 20% to $288 million; life premium revenue grew 7% and health premium revenue grew 16% year-over-year.
- FY2026 EPS guidance raised to $15.55-$15.95 per share.
- Life underwriting margin expected to exceed 50% in Q3.
- Share repurchases increased to $670-$700 million for FY2026 after a term-loan amendment.
- AI initiatives targeting administrative expense ratio of approximately 7% of premium across underwriting, claims, and agent training.
- Bermuda reinsurance subsidiary advancing with Nebraska approval secured and Indiana pending; Q3 cession planned.
Management priorities
- Expand AI applications across underwriting, claims processing, and agent training.
- Complete new reinsurance cession in Q3 and seek Indiana reciprocal jurisdiction approval.
- Continue aggressive share repurchases funded by term-loan proceeds.
- Invest in technology and digital advertising platforms to capture AI-driven search traffic.
- Maintain agent compensation adjustments focused on recruitment and retention.
Related earnings events
Financial ServicesSources
- Earnings call transcript and parsed analysis · 2026-07-23T17:03:22.480176+00:00
- FN2 earnings calendar · 2026-07-31T01:23:16.182055+00:00
- Polygon adjusted daily market bars · 2026-07-31T12:51:55.105326+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T12:51:55.103030+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.